ScripAntibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2
ScripWho: Addex/Indivior What: The companies have finally selected a clinical candidate each from their gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) research collaborati
ScripInvestors have not reacted well to Indivior plc 's business update and bad news on earnings plus a schizophrenia drug that is no longer commercially viable have sent the UK firm's share price to the
Medtech InsightClick Therapeutics, Inc. ’s acquisition of Better Therapeutics, Inc. ’s AspyreRx – the first FDA-authorized prescription digital therapeutic (PDT) for type-2 diabetes – among other assets, reflects t